SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): November 11, 2003
GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
| Massachusetts |
0-10824 |
04-2297484 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
100 Beaver Street
Waltham, Massachusetts 02453
(Address of principal executive offices, including zip code)
(781) 398-2300
(Registrant’s telephone number, including area code)
Page 1 of 4 pages.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
| (c) | Exhibits |
| 99.1 | Press Release issued by Genome Therapeutics Corp. on November 11, 2003. |
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On November 11, 2003, Genome Therapeutics Corp. issued a press release announcing its financial results for its third fiscal quarter ended September 27, 2003. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
The information in this Form 8-K is furnished under “Item 12. Results of Operations and Financial Condition” in accordance with SEC Release No. 33-8216. The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GENOME THERAPEUTICS CORP. | ||||||||
| By: | /s/ STEVEN M. RAUSCHER | |||||||
| Name: Steven M. Rauscher Title: Chief Executive Officer and President | ||||||||
Date: November 13, 2003
3
EXHIBIT INDEX
| Exhibit Number |
Description | |
| 99.1 | Press Release issued by Genome Therapeutics Corp. on November 11, 2003. | |
4